ClinicalTrials.gg
Drug

Dolutegravir clinical trials

Also written GSK1349572, Tivicay, DTG and Tivicay 50 mg.

studies test it
170
open now
18
in phase 3
44
first study started
2007

Counted the way a researcher would: Dolutegravir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Dolutegravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Dolutegravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 Aug 2013 · TIVICAY · NDA 204790 (FDA, Drugs@FDA)
European Union
16 Jan 2014 · Tivicay · EMEA/H/C/002753 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Dolutegravir
57
Dolutegravir 50 mg
15
Dolutegravir (DTG)
6
Tivicay, DTG
3
Dolutegravir 50mg od
2

Brand

Tivicay
22
Tivicay 50 mg
2
TIVICAY PD
1

Development codes

GSK1349572
26

Other names

DTG
15

In one entry with another drug

Given together, or one or the other

dual therapy
6
DTG/3TC
5
Dolutegravir/abacavir/lamivudine
2
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
2

Studies by the year they started

170 studies that test it; most in 2015 (16)

Studies that test Dolutegravir, by start year
YearStudies
20071
20085
20097
20108
201114
20124
20133
201414
201516
201616
201713
20187
201914
20205
202110
20229
20237
20246
20255
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
55
Phase 2
34
Phase 3
44
Phase 4
41
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 68 · Other 102

ViiV Healthcare (54) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · GlaxoSmithKline (8) · PENTA Foundation (4) · ANRS, Emerging Infectious Diseases (4) · University of North Carolina, Chapel Hill (4) · St Stephens Aids Trust (4) · Fundacion SEIMC-GESIDA (3)

Often tested with

Tested in the same studies.

Lamivudine (37) · Darunavir (8) · Abacavir (8) · Emtricitabine (7) · Tenofovir alafenamide (7) · Tenofovir (6) · Ritonavir (6) · Dolutegravir Sodium/Lamivudine (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Dolutegravir is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 6, 1 in phase 3

Studies that test Dolutegravir, phase 3 first.

Studies

Open first, then newest update. How each study uses Dolutegravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 170

See all 170 studies that test Dolutegravir →

Given beside what is tested · 20 — Dolutegravir is usual care or a partner of the new treatment
As the comparator · 17 — what is tested is compared with Dolutegravir

Codes

What other systems call Dolutegravir · ClinicalTrials.gg INT006890

  • MeSH (NLM) D000099226DolutegravirConfirmed NLM, Wikidata
  • UNII (FDA) DKO1W9H7M1DOLUTEGRAVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 1433868Confirmed FDA, Wikidata
  • Wikidata Q937224dolutegravirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C121543DolutegravirOne source FDA
  • DrugBank DB08930One source Wikidata

Also registered as dolutegravir sodium (UNII 1Q1V9V5WYQ · RxNorm 1433867), dolutegravir sodium monohydrate (UNII 0E1T06685X), dolutegravir, (4s,12ar)- (UNII S3BN9Q9EHW) and dolutegravir, (s,s)- (UNII FGD6SPP2VH).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.